Horizon Provides Assurances That Tepezza Sales Are Set To Soar
Guidance Maintained For 30% Growth In 2022
Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.
